Table 4. Incidence of common adverse events among patients with advanced prostate cancer receiving either MAB or castration alone.

	All grades in MAB group (%)/grade ≥ 3			All grades in castration alone group (%)/grade ≥ 3 (n = 308)
	Bicalutamide subgroup (n = 156)	Flutamide subgroup (n = 144)	Total (n = 300)
Hot flushes	63 (40.4)/10	61 (42.7)/7	124 (41.3)/17	132 (42.8)/13
Fatigue	47 (30.1)/4	40 (27.7)/5	87 (29.0)/9	84 (27.3)/7
Diarrhoea	17 (10.9)/6	37 (25.7)/4	54 (18.0)/10	17 (5.5)/2
Increased ALT/AST	16 (10.3)/0	39 (27.1)/2	54 (18.0)/2	24 (7.8)/0
Back pain	25 (16.0)/5	22 (15.3)/6	47 (15.6)/11	37 (12)/6
Nausea/vomiting	17 (10.9)/3	28 (19.4)/6	45 (15.0)/9	25 (8.1)/1
Constipation	25 (16.0)/3	15 (10.4)/1	40 (13.3)/4	23 (7.5)/1
Dyspnea	21 (13.5)/0	19 (13.2)/0	40 (13.3)/0	35 (11.4)/0
Abdominal pain	13 (8.3)/0	20 (13.9)/0	33 (11.0)/0	19 (6.2)/0
Anaemia	14 (9.0)/0	11 (7.6)/0	25 (8.3)/0	25 (8.1)/0
Haematuria	12 (7.7)/1	2 (1.4)/0	14 (4.7)/1	4 (1.3)/1
Visual disorder	8 (5.1)/1	2 (1.4)/0	10 (3.3)/0	0 (0.0)/0

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; MAB, maximal androgen blockade.